Clinical Trial Update: BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of BL22 immunotoxin in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• BL22 Immunotoxin (BL22 immunotoxin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | Phase 1 | Status: WITHDRAWN